60 Degrees Pharmaceuticals (SXTP) Projected to Post Earnings on Thursday

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is expected to be issuing its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($2.28) per share and revenue of $0.5350 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

60 Degrees Pharmaceuticals Stock Performance

Shares of SXTP stock opened at $2.12 on Thursday. The stock has a fifty day moving average price of $3.12 and a 200 day moving average price of $4.16. The stock has a market cap of $2.25 million, a PE ratio of -0.15 and a beta of 3.01. 60 Degrees Pharmaceuticals has a 1 year low of $1.36 and a 1 year high of $17.68.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright raised their price target on 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Ascendiant Capital Markets decreased their price objective on shares of 60 Degrees Pharmaceuticals from $12.00 to $11.20 and set a “buy” rating on the stock in a research report on Friday, November 28th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $17.60.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.